Survodutide
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
Boehringer Ingelheim · Phase 1 · Completed · Enrollment 88
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| BI 1820237 treatment group | n/r | n/r | n/r | n/r | n/r |
| Placebo group | n/r | n/r | n/r | n/r | n/r |
| BI 1820237 + semaglutide treatment group | n/r | n/r | n/r | n/r | n/r |
| placebo + semaglutide group | n/r | n/r | n/r | n/r | n/r |
| BI 1820237 + BI 456906 treatment group | n/r | n/r | n/r | n/r | n/r |
| placebo + BI 456906 group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.